





Investment Summit October 19, 2010

Presented by: Jenni Pilcher, CFO

Contact: jenni.pilcher@mesoblast.com



Company Snapshot

Regenerative Medicine Company

Head Office Melbourne

□ Founder and CEO → Professor Silviu Itescu

Acquired platform technology from Hansen Institute – Uni of SA

Listed in Dec 2004 - ASX ("MSB")

□ Owns 38% of Angioblast Systems → Acquisition Pending




Platform Technology

Adult Stem Cells = "MPCs" (Mesenchymal Precursor Cells)





"Off-the-Shelf" Product Pipeline



Follow-on Products Eye Disease (AMD) Intervertebral Disc Repair Diabetes



Lead Product Targets

Lead Products	Target Disease	Latest Results/Stage of development	Phase III Start
Cord Blood Expansion	Bone Marrow Transplantation	25 patients transplanted = 80% 100 day survival with sustained engraftment; 38% for non-expanded cord blood (historical)	2011 (orphan drug)
Revascor™	Congestive Heart Failure	1 st cohort (Ph II) – improved heart muscle function at both 3 and 6 months	2012
NeoFuse™	Spinal Fusions (lumbar and cervical)	Mid Phase II – interim results expected Q1 2011	2012



Commercialisation

Lead Products	Patient Population	Alternative Treatments	MSB Competitive Advantage	Launch
Cord Blood Expansion for Bone Marrow Transplants	 60k BMT procedures 	BMT's from unrelated donors	 Reduces GVHD Broader market (across ethnic groups) 	2014
Congestive Heart Failure	 5m existing + 600k diagnosed annually in the US alone 	none	 Improved heart muscle function, Quality of Life Increased survival rates 	2015/16
Spinal Fusion	 500k procedures annually in the US 	Infuse (BMP2) Autograft	 Safer no second surgery 	2015/16



Financials as at 30 June 2010

